Go or no go? UCB bids to make a mark in psoriasis
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
Clearside’s long-acting eye project shows promise
But data are early, and other groups are also developing less frequent injections for wet AMD.
Go or no go? Novartis eyes a big new growth driver
The biggest approval decision in October will involve Novartis’s eye asset Beovu, while Biogen and Alkermes face a key verdict in MS.
Clearside’s future clouds over
After failing in retinal vein occlusion, the prospects for the eye project Xipere – and Clearside Biomedical itself – hinge on the smaller uveitis indication.
